<--- Back to Details
First PageDocument Content
Medicine / Non-nucleoside reverse transcriptase inhibitors / Cyclopropanes / Organofluorides / Bristol-Myers Squibb / Antiretroviral drug / Nevirapine / Efavirenz / Viral load / Chemistry / Organic chemistry / HIV/AIDS
Medicine
Non-nucleoside reverse transcriptase inhibitors
Cyclopropanes
Organofluorides
Bristol-Myers Squibb
Antiretroviral drug
Nevirapine
Efavirenz
Viral load
Chemistry
Organic chemistry
HIV/AIDS

The pattern and predictors of mortality of HIV/AIDS patients with neurologic manifestation in Ethiopia: a retrospective study

Add to Reading List

Source URL: www.ncbi.nlm.nih.gov

Download Document from Source Website

File Size: 225,99 KB

Share Document on Facebook

Similar Documents

PRESS RELEASE Particle Sciences to Develop Antiretroviral Formulations as part of MOTIF BETHLEHEM, PA- October 10, 2012 ‐ Particle Sciences, a leading drug delivery CRO, has been selected to be the formulation arm of a

PRESS RELEASE Particle Sciences to Develop Antiretroviral Formulations as part of MOTIF BETHLEHEM, PA- October 10, 2012 ‐ Particle Sciences, a leading drug delivery CRO, has been selected to be the formulation arm of a

DocID: 1m6of - View Document

Microsoft Word - Biographie de JF Delfraissy BIS.doc

Microsoft Word - Biographie de JF Delfraissy BIS.doc

DocID: 1gw3d - View Document

Surveillance and outbreak reports  Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy C Semaille ()1, Y Le S

Surveillance and outbreak reports Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy C Semaille ()1, Y Le S

DocID: 1gvMD - View Document

Questioning the HIV-AIDS hypothesis: 30 years of dissent

Questioning the HIV-AIDS hypothesis: 30 years of dissent

DocID: 1gtoc - View Document

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releas

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releas

DocID: 1gtlL - View Document